Prognostic value of serum γ‑glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy

Chen,Dong; Wang,Renben; Meng,Xiangjiao; Yan,Hongjiang; Jiang,Shumei; Feng,Rui; Zhu,Kunli; Xu,Xiaoqing; Dou,Xue; Jin,Linzhi

doi:10.3892/ol.2014.2456

Prognostic value of serum γ‑glutamyl transferase in unresectable hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization combined with conformal radiotherapy

Authors:
- Dong Chen
- Renben Wang
- Xiangjiao Meng
- Hongjiang Yan
- Shumei Jiang
- Rui Feng
- Kunli Zhu
- Xiaoqing Xu
- Xue Dou
- Linzhi Jin
View Affiliations

Affiliations: Department of Radiation Oncology, Shandong Cancer Hospital, Jinan, Shandong 250117, P.R. China
Published online on: August 19, 2014 https://doi.org/10.3892/ol.2014.2456
Pages: 2298-2304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of γ‑glutamyl transferase (GGT) has previously been reported to be useful in the diagnosis in hepatocellular carcinoma (HCC). The aim of the present study was to investigate the baseline serum GGT levels in patients with intermediate HCC (Barcelona Clinic Liver Cancer stage B) following treatment with transcatheter arterial chemoembolization (TACE) combined with three‑dimensional conformal radiotherapy (3DCRT). A total of 154 intermediate HCC patients with Child‑Pugh grade A were retrospectively investigated. Receiver operating characteristic (ROC) analysis was used to determine the optimal threshold for the GGT serum levels, and univariate and multivariate analyses were used to establish the prognostic factors. The median overall survival (OS) time was 24.3 months. The optimal threshold for GGT was 85 U/L (sensitivity, 75.13%; specificity, 69.81%; and area under the ROC curve, 0.763). The one‑, three‑ and five‑year OS rates were 79.9, 49.7 and 17.2%, respectively, for patients with low GGT levels (≤85 U/l) and 52.3, 22.1 and 8.5%, respectively, for patients with high GGT levels (>85 U/l) (P=0.007). The results indicated that the serum GGT level was an independent prognostic factor (hazard ratio=2.32; P=0.007) for OS. Furthermore, in subgroups stratified according to serum α‑fetoprotein, gross tumor volume and radiation dose, serum GGT was also found to correlate with OS (P<0.05). Therefore, the baseline GGT level may be a significant prognostic factor for intermediate HCC patients with Child‑Pugh grade A following TACE combined with 3DCRT.

View Figures

View References

1	Cárdenes HR: Role of stereotactic body radiotherapy in the management of primary hepatocellular carcinoma. Rationale, technique and results. Clin Transl Oncol. 11:276–283. 2009.
2	Nathan H, Schulick RD, Choti MA and Pawlik TM: Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 249:799–805. 2009.
3	Cha CH, Saif MW, Yamane BH and Weber SM: Hepatocellular carcinoma: current management. Curr Probl Surg. 47:10–67. 2010.
4	Zeng ZC, Tang ZY, Fan J, et al: A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 10:307–316. 2004.
5	Xu LT, Zhou ZH, Lin JH, et al: Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma. Eur J Surg Oncol. 37:245–251. 2011.
6	Whitfield JB: Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 38:263–355. 2001.
7	Griffith OW, Bridges RJ and Meister A: Transport of gamma-glutamyl amino acids: role of glutathione and gamma-glutamyl transpeptidase. Proc Natl Acad Sci USA. 76:6319–6322. 1979.
8	Poynard T, Zourabichvili O, Hilpert G, et al: Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology. 4:324–327. 1984.
9	Ju MJ, Qiu SJ, Fan J, et al: Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 44:635–642. 2009.
10	Zhang JB, Chen Y, Zhang B, et al: Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 23:787–793. 2011.
11	Llovet JM, Fuster J and Bruix J: Barcelona-Clínic Liver Cancer Group: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 10:S115–S120. 2004.
12	Bruix J, Sherman M, Llovet JM, et al: EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference European Association for the Study of the Liver. J Hepatol. 35:421–430. 2001.
13	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982.
14	Saheb SM, Nath VN, Kumar KP and Padmaja PP: A novel method using Seldinger’s technique for submental intubation in major craniomaxillofacial fractures: A case series. Indian J Anaesth. 58:48–50. 2014.
15	Kuo YC, Chiu YM, Shih WP, et al: Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy. Radiat Oncol. 6:762011.
16	Whitfield JB, Pounder RE, Neale G and Moss DW: Serum-glytamyl transpeptidase activity in liver disease. Gut. 13:702–708. 1972.
17	Idéo G, Morganti A and Dioguardi N: Gamma-glutamyl transpeptidase: a clinical and experimental study. Digestion. 5:326–336. 1972.
18	Hann HW, Wan S, Myers RE, et al: Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PloS one. 7:e476872012.
19	Guiu B, Deschamps F, Boulin M, et al: Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 35:1102–1108. 2012.
20	Hanigan MH: gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis. Chem Biol Interact. 111–112:333–342. 1998.
21	Pompella A, Corti A, Paolicchi A, Giommarelli C and Zunino F: Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol. 7:360–366. 2007.
22	Stark AA, Zeiger E and Pagano DA: Glutathione metabolism by γ-glutamyl transpeptidase leads to lipid peroxidation: characterization of the system and relevance to hepatocarcinogenesis. Carcinogenesis. 14:183–189. 1993.
23	Paolicchi A, Tongiani R, Tonarelli P, Comporti M and Pompella A: gamma-Glutamyl transpeptidase-dependent lipid peroxidation in isolated hepatocytes and HepG2 hepatoma cells. Free Radic Biol Med. 22:853–860. 1997.
24	Negre-Salvayre A, Auge N, Ayala V, et al: Pathological aspects of lipid peroxidation. Free Radic Res. 44:1125–1171. 2010.
25	Zhao J, Zhao Y, Wang H, Gu X, Ji J and Gao C: Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study. Nutr J. 10:492011.
26	Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 89:3070–3074. 1992.
27	Daubeuf S, Balin D, Leroy P and Visvikis A: Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol. 66:595–604. 2003.
28	Kouloulias V, Mosa E, Georgakopoulos J, et al: Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: A retrospective study. ScientificWorldJournal. 2013:7801412013.
29	Son SH, Choi BO, Ryu MR, et al: Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 78:1073–1080. 2010.
30	Li M, Zhou S, Liu X, Li P, McNutt MA and Li G: alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Lett. 249:227–234. 2007.
31	Mitsuhashi N, Kobayashi S, Doki T, et al: Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 23:e189–e197. 2008.
32	Yang X, Zhang Y, Zhang L, Zhang L and Mao J: Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett. 271:281–293. 2008.
33	Ho CM, Wu CY, Lee PH, Lai HS, Ho MC, Wu YM and Hu RH: Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma. Ann Surg Oncol. 20:2526–2533. 2013.
34	Siripongsakun S, Wei SH, Lin S, et al: Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 29:157–164. 2014.
35	Tsai YJ, Hsu CY, Huang YH, et al: Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int. 5:975–984. 2011.
36	Kohles N, Nagel D, Jüngst D, Durner J, Stieber P and Holdenrieder S: Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumor Biol. 33:33–40. 2012.